Role of Immune Checkpoint Inhibitor Therapy in Advanced EGFR-Mutant Non-Small Cell Lung Cancer

QR Code

Role of Immune Checkpoint Inhibitor Therapy in Advanced EGFR-Mutant Non-Small Cell Lung Cancer

Over the last decade, the treatment of advanced non-small cell lung cancer (NSCLC) has undergone rapid changes with innovations in oncogene-directed therapy and immune checkpoint inhibitors. In patients with epidermal growth factor receptor (EGFR) gene mutant (EGFRm) NSCLC, newer-generation tyrosine...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Nathaniel Wiest, Umair Majeed, Karan Seegobin, Yujie Zhao, Yanyan Lou, Rami Manochakian
Format:	article
Langue:	EN
Publié:	Frontiers Media S.A. 2021
Sujets:	Non-small cell lung cancer lung cancer EGFR tyrosine kinase inhibitor immune-mediated adverse effects immune checkpoint inhibitor (ICI) Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Accès en ligne:	https://doaj.org/article/8a8afaf9374b4c2f8f1ca6eb45e8a49c
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Front-Line ICI-Based Combination Therapy Post-TKI Resistance May Improve Survival in NSCLC Patients With EGFR Mutation
par: Tian Tian, et autres
Publié: (2021)

Favorable Immune Microenvironment in Patients with EGFR and MAPK Co-Mutations
par: Yang W, et autres
Publié: (2020)

A Network Comparison on Safety Profiling of Immune Checkpoint Inhibitors in Advanced Lung Cancer
par: Yi-Dan Yan, et autres
Publié: (2021)

Uncommon EGFR mutations in cytological specimens of 1,874 newly diagnosed Indonesian lung cancer patients
par: Syahruddin E, et autres
Publié: (2018)

Oligoprogression in Non-Small Cell Lung Cancer
par: Daijiro Harada, et autres
Publié: (2021)

Efficacy of Targeted Inhibitors in Metastatic Lung Squamous Cell Carcinoma With EGFR or ALK Alterations
par: Whitney E. Lewis, PharmD, et autres
Publié: (2021)

Immunotherapy in the First-Line Treatment of NSCLC: Current Status and Future Directions in China
par: Anwen Xiong, et autres
Publié: (2021)

Comparison of the efficacy of first-line therapy with different generations of EGFR tyrosine kinase inhibitors in patients with advanced EGFR-associated non-small cell lung cancer: a network meta-analysis of overall survival data
par: Alexey A. Bogdanov, et autres
Publié: (2021)

Monitoring cfDNA in Plasma and in Other Liquid Biopsies of Advanced EGFR Mutated NSCLC Patients: A Pilot Study and a Review of the Literature
par: Michela Verzè, et autres
Publié: (2021)

Progress in the Application of Immune Checkpoint Inhibitor-Based Immunotherapy for Targeting Different Types of Colorectal Cancer
par: Rui He, et autres
Publié: (2021)

Clinical Research Progress of Radiotherapy Combined with Immune Checkpoint Inhibitors on NSCLC
par: ZHU Kuikui, et autres
Publié: (2021)

Identification and Validation of Immune-Related Gene for Predicting Prognosis and Therapeutic Response in Ovarian Cancer
par: Zhao-Cong Zhang, et autres
Publié: (2021)

Immune-mediated adverse events in immune checkpoint inhibitors therapy: literature review
par: Marina A. Lyadova, et autres
Publié: (2021)

Comparison of afatinib and osimertinib effect on overall survival in first-line drug treatment of EGFR-positive metastatic non-small cell lung cancer: network meta-analysis
par: Sergey V. Goryaynov
Publié: (2021)

Immune Checkpoint Inhibitors With or Without Bone-Targeted Therapy in NSCLC Patients With Bone Metastases and Prognostic Significance of Neutrophil-to-Lymphocyte Ratio
par: Alberto Bongiovanni, et autres
Publié: (2021)

Unravelling Checkpoint Inhibitor Associated Autoimmune Diabetes: From Bench to Bedside
par: Linda Wu, et autres
Publié: (2021)

Profile of rociletinib and its potential in the treatment of non-small-cell lung cancer
par: Tran PN, et autres
Publié: (2016)

Risk Factors, Incidence, and Prognosis of Thromboembolism in Cancer Patients Treated With Immune Checkpoint Inhibitors
par: Xue-lin Zou, et autres
Publié: (2021)

HER2 Amplification in Advanced NSCLC Patients After Progression on EGFR-TKI and Clinical Response to EGFR-TKI Plus Pyrotinib Combination Therapy
par: Gan J, et autres
Publié: (2021)

Progression‐free survival assessed per immune‐related or conventional response criteria, which is the better surrogate endpoint for overall survival in trials of immune‐checkpoint inhibitors in lung cancer: A systematic review and meta‐analysis
par: Guang‐Li Zhu, et autres
Publié: (2021)

Pan-Cancer Analysis Reveals Alternative Splicing Characteristics Associated With Immune-Related Adverse Events Elicited by Checkpoint Immunotherapy
par: Xiujing He, et autres
Publié: (2021)

Analysis of characteristics and predictive factors of immune checkpoint inhibitor-related adverse events
par: Rilan Bai, et autres
Publié: (2021)

Patterns and outcomes of immune-related adverse events in solid tumor patients treated with immune checkpoint inhibitors in Thailand: a multicenter analysis
par: Nuttapong Ngamphaiboon, et autres
Publié: (2021)

MET Amplification and Efficacy of Nivolumab in Patients With NSCLC
par: Katsuhiro Yoshimura, MD, PhD, et autres
Publié: (2021)

GDPLichi: a DNA Damage Repair-Related Gene Classifier for Predicting Lung Adenocarcinoma Immune Checkpoint Inhibitors Response
par: Yang Leng, et autres
Publié: (2021)

Clinical Trial Progress and Application of Immune Checkpoint Inhibitors  in the Treatment of Small Cell Lung Cancer
par: Huiqiu ZHANG, et autres
Publié: (2021)

Real-World Approach for Molecular Analysis of Acquired EGFR Tyrosine Kinase Inhibitor Resistance Mechanisms in NSCLC
par: Liesbeth M. Hondelink, MD, et autres
Publié: (2021)

Musarin, a novel protein with tyrosine kinase inhibitory activity from Trametes versicolor, inhibits colorectal cancer stem cell growth
par: YingYing He, et autres
Publié: (2021)

Clinical case of long-term use of durvalumab in the treatment of advanced small-cell lung cancer
par: Galina B. Statsenko, et autres
Publié: (2020)

Factors associated with immunotherapy respond and survival in advanced non-small cell lung cancer patients
par: Yahua Wu, et autres
Publié: (2022)

Impact of Immune-Related Adverse Events on Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Hepatocellular Carcinoma
par: Kennedy Yao Yi Ng, et autres
Publié: (2021)

Profile of entrectinib and its potential in the treatment of ROS1-positive NSCLC: evidence to date
par: Facchinetti F, et autres
Publié: (2019)

Outcome of uncommon EGFR mutation positive newly diagnosed advanced non-small cell lung cancer patients: a single center retrospective analysis
par: Kate S, et autres
Publié: (2019)

Combination of EGFR-TKIs with chemotherapy versus chemotherapy or EGFR-TKIs alone in advanced NSCLC patients with EGFR mutation
par: Wen M, et autres
Publié: (2018)

Efficacy and Safety of Adding Immune Checkpoint Inhibitors to Neoadjuvant Chemotherapy Against Triple-Negative Breast Cancer: A Meta-Analysis of Randomized Controlled Trials
par: Yunhai Li, et autres
Publié: (2021)

Correlation Between Peripheral Blood Biomarkers and Efficacy of PD-1/PD-L1 Inhibitors Treatment on Lung Cancer
par: KE Ping, et autres
Publié: (2021)

Age-Based Disparities in Metastatic Melanoma Patients Treated in the Immune Checkpoint Inhibitors (ICI) Versus Non-ICI Era: A Population-Based Study
par: Mohammed Safi, et autres
Publié: (2021)

Body mass index is not associated with survival outcomes and immune-related adverse events in patients with Hodgkin lymphoma treated with the immune checkpoint inhibitor nivolumab
par: Rosaria De Filippi, et autres
Publié: (2021)

Dramatic, significant metabolic response to a one‐time pembrolizumab treatment following a relapse of pre‐existing organizing pneumonia in a patient with advanced non‐small cell lung cancer: A case report
par: Motoyasu Kato, et autres
Publié: (2021)

Immunotherapy in Non-Small Cell Lung Cancer With Actionable Mutations Other Than EGFR
par: Karan Seegobin, et autres
Publié: (2021)